Compare AbCellera Biologics Inc (ABCL) vs Zoom Video Communications, Inc. (ZM) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Zoom Communications (ZM) trades at $85.68, down 1.68% on the day, with a bearish technical outlook despite strong fundamentals. The stock shows robust profitability with 77.4% gross margins and 42% net income margin, while trading at attractive valuation multiples (P/E 12.5x, P/S 5.2x). Recent Q1 2026 earnings beat expectations, and the company continues AI-driven growth through acquisitions like Common Room and new product launches.

ZM presents a compelling value opportunity with significant upside to the $118.79 consensus price target, though technical weakness and competitive pressures from Microsoft and Google remain headwinds. The company's strong cash position ($7.7B) and strategic Anthropic investment provide additional upside catalysts, making it attractive for patient investors despite near-term bearish technical signals.